Showing results (671-680 of 735) with videos related to

Sort By:
Pageof 74
European Journal of Cancer (Oxford, England : 1990)|September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialAlexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.
The New England Journal of Medicine|April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Nature Medicine|June 14, 2024
Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichmentAdam J Widman, Minita Shah, Amanda Frydendahl, et al.
Lancet (London, England)|June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
The New England Journal of Medicine|September 12, 2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
JAMA Oncology|January 3, 2020
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical TrialAlexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2021
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanomaAlexander Mm Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.
Cancer|July 17, 2020
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trialRobert J Motzer, Bernard Escudier, Saby George, et al.
NEJM Evidence|February 6, 2024
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III MelanomaAlexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
The Lancet. Infectious Diseases|September 14, 2024
Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling studyTimothy W Russell, Hermaleigh Townsley, Joel Hellewell, et al.
Pageof 74